Drug Discovery crystal ball gazing for the year ahead. And the hottest prospects are discussed below.
We already have 5 CDER (FDA) approvals this year which are tantalizing new treatments for patients -
Daridorexant (Quviviq), a selective dual antagonist of the orexin receptors OX1 and OX2 used for the treatment of insomnia. Idorsia Pharmaceuticals Ltd
Abrocitinib (Cibinqo), a new JAK1 kinase inhibitor used for the treatment of atopic dermatitis. Pfizer
Tebentafusp (Kimmtrak), a bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat uveal melanoma (eye cancer). Immunocore
Faricimab (Vabysmo), a bispecific mAb, a VEGF, and Ang-2 inhibitor used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Genentech
Sutimlimab (Enjaymo), a mAb that is used to treat adults with cold agglutinin disease (CAD). Sanofi
But what are the hottest and 'potentially' most lucrative drug approvals on the horizon this year?
- Adagrasib (MRTX-849), a KRASG12C inhibitor for the treatment of various cancers.
- Deucravacitinib (BMS-986165), the first novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor for the treatment of multiple immune diseases including plaque psoriasis.
- Donanemab (LY3002813), a humanized IgG1 monoclonal antibody targeted against an epitope at the N-terminal of a specific type of amyloid beta (Aβ) for the treatment of Alzheimer's Disease (AD).
- Tirzepatide, an analogue of the gastric inhibitory polypeptide (GIP), a human hormone that stimulates the release of insulin from the pancreas, for the treatment of Type 2 diabetes.
- Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, which encompasses both hereditary ATTR (hATTR) amyloidosis and wild-type ATTR (wtATTR) amyloidosis.
- Mavacamten, a potential first-in-class, oral, allosteric modulator of cardiac myosin, is under investigation for the treatment of conditions in which excessive cardiac contractility and impaired diastolic filling of the heart are the underlying cause.
- Relatlimab (BMS-986016) is a mAb designed for the treatment of melanoma.
- Betibeglogene autotemcel (Zynteglo), gene therapy for the treatment of beta-thalassemia.
A big year for Alzheimer's disease. A big year for and
Continue reading
This content available exclusively for BPT Mebmers
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.
